Home
About
Overview
Sharing Data
ORCID
Help
History (12)
Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.
Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives.
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience.
Phenytoin
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
See All 12 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35.
View in:
PubMed
subject areas
Adult
Aged
Antibodies, Monoclonal
Antineoplastic Agents
B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Female
Humans
Immunoglobulin G
Lung Neoplasms
Male
Middle Aged
Programmed Cell Death 1 Receptor
Survival Analysis
Taxoids
authors with profiles
Marina Chiara Garassino
Everett Vokes